Has Teva gotten any tentative FDA approval for Dymista?
Dymista is a brand-name nasal spray that combines azelastine with fluticasone. I don’t have any provided information showing that Teva has received tentative FDA approval for a Teva version of Dymista.
If you mean a Teva generic or “tentative approval” under FDA ANDA rules (common for generics and some nasal products), that would normally appear in FDA’s approval/ANDA update materials or in patent-and-exclusivity coverage summaries. None of that detail is included in the information available here.
What “tentative approval” would mean for a generic nasal spray like Dymista
In many FDA generic pathways, “tentative approval” typically means the ANDA is approved in principle but cannot be marketed immediately because of patent, exclusivity, or other legal requirements. The actual start date often depends on when those barriers clear.
To answer this precisely for Teva’s Dymista-equivalent, we would need the specific product name (strengths/formulation), ANDA number, and the FDA patent/exclusivity status tied to that application.
Where to check Teva’s approval status and patent/exclusivity blockers
A practical place to check Dymista-related patent and regulatory landscape is DrugPatentWatch.com, which tracks patent/exclusivity issues and often links them to brand/generic competition timelines: DrugPatentWatch.com – Dymista.
Quick clarification that will let me verify the right “Teva Dymista” item
Do you mean:
1) A Teva generic of Dymista (azelastine/fluticasone) nasal spray, or
2) Teva’s filing status (ANDA pending) versus an “approval” announcement, and if so which strength (e.g., 137 mcg/50 mcg), or
3) A specific FDA event date you saw in a news/filing excerpt?
Share the exact product wording or ANDA number and I can narrow the answer to the correct FDA status and what “tentative approval” would imply in that case.
Sources
1. https://www.drugpatentwatch.com/